http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 05 Mar 2026 02:00:00 +0000 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Press+Releases/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html <p> HAMBURG, Germany &amp; MUNICH--(BUSINESS WIRE)-- GAIA, the pioneer in evidence-based digital therapeutics and Daiichi Sankyo Europe, today announced an exclusive strategic partnership to commercialize lipodia upon regulatory approval1. </p><p id="news-body-cta">This press release features multimedia. View the full release here: <a target="_blank" href="https://www.businesswire.com/news/home/20260224658973/en/" rel="nofollow">https://www.businesswire.com/news/home/20260224658973/en/</a></p><div id="bwbodyimg" style="width: 480px; float:left; padding-left:0px; padding-right:20px; padding-top:0px; padding-bottom:0px;"><img src="https://mms.businesswire.com/media/20260224658973/en/2729048/4/Dr._med._Mario_Weiss_CEO_GAIA_16-9.jpg" alt="Dr. Mario Weiss, Founder &amp; CEO of GAIA AG" /><p style="font-size:85%;">Dr. Mario Weiss, Founder &amp; CEO of GAIA AG</p></div><p> This digital therapeutic is designed to support adults living with hypercholesterolemia. The comprehensive collaboration brings together GAIA’s long-standing expertise in developing clinically validated non-pharmacological interventions with Daiichi Sankyo’s http://www.streetinsider.com/Business+Wire/GAIA+and+Daiichi+Sankyo+Europe+Enter+Exclusive+Partnership+to+Launch+Next-Generation+Digital+Therapeutic+for+Cardiovascular+Care+in+Europe./26113914.html Thu, 05 Mar 2026 02:00:00 +0000 4568 A.40047721 A.60012013 DSNKY O.00277477 O.07020545 O.22492915 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html <p> TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&amp;D, effective April 1, 2026. </p><p> Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring needed medicines to patients. He will join from venture capital firm Syncona Investment Management, where he was an Executive Partner responsible for starting new biotech companies based on scientific http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html Thu, 19 Feb 2026 19:00:00 +0000 4568 4568 A.41351696 A.50200199 DSNKY O.01899048 O.17791244 O.22492915 O.30747551 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html <p> TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&amp;D, effective April 1, 2026. </p><p> Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring needed medicines to patients. He will join from venture capital firm Syncona Investment Management, where he was an Executive Partner responsible for starting new biotech companies based on scientific http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html Thu, 19 Feb 2026 19:00:00 +0000 4568 4568 A.41351696 A.50200199 DSNKY O.01899048 O.17791244 O.22492915 O.30747551 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html <p> TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&amp;D, effective April 1, 2026. </p><p> Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring needed medicines to patients. He will join from venture capital firm Syncona Investment Management, where he was an Executive Partner responsible for starting new biotech companies based on scientific http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html Thu, 19 Feb 2026 19:00:00 +0000 4568 4568 A.41351696 A.50200199 DSNKY O.01899048 O.17791244 O.22492915 O.30747551 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html <p> TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&amp;D, effective April 1, 2026. </p><p> Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring needed medicines to patients. He will join from venture capital firm Syncona Investment Management, where he was an Executive Partner responsible for starting new biotech companies based on scientific http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html Thu, 19 Feb 2026 19:00:00 +0000 4568 4568 A.41351696 A.50200199 DSNKY O.01899048 O.17791244 O.22492915 O.30747551 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html <p> TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&amp;D, effective April 1, 2026. </p><p> Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring needed medicines to patients. He will join from venture capital firm Syncona Investment Management, where he was an Executive Partner responsible for starting new biotech companies based on scientific http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html Thu, 19 Feb 2026 19:00:00 +0000 4568 4568 A.41351696 A.50200199 DSNKY O.01899048 O.17791244 O.22492915 O.30747551 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html <p> TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&amp;D, effective April 1, 2026. </p><p> Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring needed medicines to patients. He will join from venture capital firm Syncona Investment Management, where he was an Executive Partner responsible for starting new biotech companies based on scientific http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html Thu, 19 Feb 2026 19:00:00 +0000 4568 4568 A.41351696 A.50200199 DSNKY O.01899048 O.17791244 O.22492915 O.30747551 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html <p> TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&amp;D, effective April 1, 2026. </p><p> Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring needed medicines to patients. He will join from venture capital firm Syncona Investment Management, where he was an Executive Partner responsible for starting new biotech companies based on scientific http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html Thu, 19 Feb 2026 19:00:00 +0000 4568 4568 A.41351696 A.50200199 DSNKY O.01899048 O.17791244 O.22492915 O.30747551 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html <p> TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&amp;D, effective April 1, 2026. </p><p> Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring needed medicines to patients. He will join from venture capital firm Syncona Investment Management, where he was an Executive Partner responsible for starting new biotech companies based on scientific http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html Thu, 19 Feb 2026 19:00:00 +0000 4568 4568 A.41351696 A.50200199 DSNKY O.01899048 O.17791244 O.22492915 O.30747551 http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html <p> TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&amp;D, effective April 1, 2026. </p><p> Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring needed medicines to patients. He will join from venture capital firm Syncona Investment Management, where he was an Executive Partner responsible for starting new biotech companies based on scientific http://www.streetinsider.com/Press+Releases/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html Thu, 19 Feb 2026 19:00:00 +0000 4568 4568 A.41351696 A.50200199 DSNKY O.01899048 O.17791244 O.22492915 O.30747551 http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html <p> TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&amp;D, effective April 1, 2026. </p><p> Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring needed medicines to patients. He will join from venture capital firm Syncona Investment Management, where he was an Executive Partner responsible for starting new biotech companies based on scientific http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html Thu, 19 Feb 2026 19:00:00 +0000 4568 4568 A.41351696 A.50200199 DSNKY O.01899048 O.17791244 O.22492915 O.30747551 http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html <p> TOKYO &amp; BASKING RIDGE, N.J.--(BUSINESS WIRE)-- Daiichi Sankyo Company, Limited (TSE: 4568) has appointed John Tsai, MD to succeed Ken Takeshita, MD, who is stepping down as Global Head of R&amp;D, effective April 1, 2026. </p><p> Dr. Tsai will bring more than 25 years of proven leadership and experience driving innovation to further grow the rich Daiichi Sankyo pipeline, as well as lead the acceleration of new science to bring needed medicines to patients. He will join from venture capital firm Syncona Investment Management, where he was an Executive Partner responsible for starting new biotech companies based on scientific http://www.streetinsider.com/Business+Wire/Daiichi+Sankyo+Appoints+John+Tsai%2C+MD+as+Global+Head+of+R%26amp%3BD/26031546.html Thu, 19 Feb 2026 19:00:00 +0000 4568 4568 A.41351696 A.50200199 DSNKY O.01899048 O.17791244 O.22492915 O.30747551